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Abstract
Background
Tuberculosis (TB) patients incur large costs for care seeking, diagnosis, and treatment. To
understand the magnitude of this financial burden and its main cost drivers, the Lao People’s
Democratic Republic (PDR) National TB Programme carried out the first national TB patient
cost survey in 2018–2019.
Method
A facility-based cross-sectional survey was conducted based on a nationally representative
sample of TB patients from public health facilities across 12 provinces. A total of 848 TB
patients including 30 drug resistant (DR)-TB and 123 TB-HIV coinfected patients were inter-
viewed using a standardised questionnaire developed by the World Health Organization.
Information on direct medical, direct non-medical and indirect costs, as well as coping mech-
anisms was collected. We estimated the percentage of TB-affected households facing cata-
strophic costs, which was defined as total TB-related costs accounting for more than 20% of
annual household income.
Result
The median total cost of TB care was US$ 755 (Interquartile range 351–1,454). The costs
were driven by direct non-medical costs (46.6%) and income loss (37.6%). Nutritional
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supplements accounted for 74.7% of direct non-medical costs. Half of the patients used sav-
ings, borrowed money or sold household assets to cope with TB. The proportion of unem-
ployment more than doubled from 16.8% to 35.4% during the TB episode, especially among
those working in the informal sector. Of all participants, 62.6% of TB-affected households
faced catastrophic costs. This proportion was higher among households with DR-TB
(86.7%) and TB-HIV coinfected patients (81.1%).
Conclusion
In Lao PDR, TB patients and their households faced a substantial financial burden due to
TB, despite the availability of free TB services in public health facilities. As direct non-medi-
cal and indirect costs were major cost drivers, providing free TB services is not enough to
ease this financial burden. Expansion of existing social protection schemes to accommo-
date the needs of TB patients is necessary.
Introduction
Tuberculosis (TB) is one of the major public health concerns globally [1]. TB patients usually
incur a substantial financial cost for care seeking, diagnosis, and treatment [2]. Poverty is
already known to be linked to a higher risk of TB infection and disease, delays in diagnosis,
and poor treatment adherence, which can result in adverse treatment outcomes and the devel-
opment of multi-drug resistant (MDR)-TB [2–5]. TB also worsens poverty as TB patients
often lose the ability to work, leading to income loss [5–7]. In addition, households affected by
TB will often mobilize funds for TB treatment by dissaving, selling assets, or taking out loans,
which makes them poorer, and traps them in a cycle of poverty and disease [8–10].
Considering the global burden of TB and the social, human and financial consequences of
TB, the World Health Organization (WHO) has developed the End TB Strategy, which out-
lines the ambitious goal of ending the TB epidemic worldwide by 2030 [11]. Recognizing the
need to address the financial burden due to TB, the Strategy promotes assessment of TB
patient costs and set a target of zero “catastrophic costs” for TB-affected families, in the context
of Universal Health Coverage, in addition to two traditional epidemiological targets (reduced
incidence and deaths) [11].
To establish the baseline against which to monitor the progress towards the elimination of
catastrophic costs, WHO recommends that a nationally representative survey be carried out.
These surveys are prioritised for the 30 high TB burden countries [11]. In 2015, WHO devel-
oped a generic protocol and data collection tool to support countries in planning and imple-
menting the national TB patient cost surveys, which were later refined and published as a
handbook in 2017 [12]. The WHO-recommended data collection tool is designed to collect a
range of cost data including direct medical costs (i.e. costs for medical consultations, examina-
tions, drugs, and hospitalization), direct non-medical costs (i.e. transportation, foods and
accommodation), and indirect costs (i.e. loss of income). Based on this information, cata-
strophic costs attributable to TB can be calculated. “Catastrophic costs due to TB” refers to
medical and non-medical out-of-pocket payments and indirect costs exceeding a given thresh-
old (e.g. 20%) of the household’s income [11, 12].
The Lao PDR National TB Programme (NTP) has developed their National TB Strategic
Plan 2017–2020 which is aligned with the WHO’s End TB Strategy and the Regional
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Framework for Action on Implementation of the End TB Strategy in the Western Pacific
2016–2020 [11, 13]. One of the key indicators is: “Zero TB affected families facing catastrophic
costs due to TB” [14]. It was therefore prerequisite for the NTP to conduct a national TB
patient cost survey to establish a baseline of the target and inform policies and strategies. The
study objectives were to assess the financial burden of TB from the patient perspective and to
estimate the proportion of households experiencing catastrophic costs due to TB, by drug-sus-
ceptibility and HIV status. This survey also assessed major cost drivers of patients’ expenditure
during TB episode and associated risk factors for facing catastrophic costs due to TB.
Method
Study setting
Lao PDR is a landlocked country surrounded by China, Viet Nam, Cambodia, and Thailand,
and the majority of the country is mountainous and forested [15, 16]. The population size was
6.9 million in 2017, and the majority of the population (60%) live in rural areas [17]. The coun-
try is divided into one capital city (Vientiane Capital) and 17 provinces. The capital is located
on the banks of Mekong river nearby to the border with Thailand, and the population size was
820,940 in 2015 [18]. Lao PDR has gross domestic product (GDP) growth average at 7.8%, and
is a lower middle income country with US$ 14.5 billion in Gross National Income (GNI) and a
gross national income per capita of US$ 2,150 per annum in 2016 [19].
Lao PDR has a high burden of TB [1]. The first national TB prevalence survey in Lao PDR,
conducted in 2010–2011, revealed that the prevalence of bacteriologically confirmed pulmo-
nary TB was estimated at 237 cases per 100,000 population [20]. According to the WHO’s esti-
mates, the TB incidence rate remained high in 2018, at 162 cases per 100,000 population (all
forms of TB), while the incidence rate of HIV positive TB and Multidrug-/rifampicin-resistant
TB (MDR/RR-TB) were 10 and 2.2 cases per 100,000 respectively [1, 21]. The TB mortality
rate in Lao PDR was 33.8 cases per 100,000 population in 2017 [1, 21].
In Lao PDR, approximately 20% of the total population work in the formal sector and are
covered by a comprehensive benefit schemes such as State Authority for Social Security
(SASS) and Social Security Organization (SSO) under the National Social Security Fund
(NSSF). The NSSF includes health insurance, sickness benefits, and unemployment benefits
[22]. The tax-based National Health Insurance (NHI) scheme was launched in 2016. The NHI
covered 60% of the population as of 2016, and the coverage was expected to reach more than
70% in 2017 [23]. The national health insurance bureau has recently reported that the coverage
reached 79.3% in 2019. All health services defined by the Essential Health Service Package
(EHSP) at public health facilities in the country are covered by the NHI scheme [24, 25]. Costs
for TB diagnosis and treatment and hospitalization for all TB patients are covered by the NTP
and NHI who cover the cost of sputum examinations including smear, culture and Xpert
MTB/RIF (a rapid molecular test), testing and counselling for HIV, and anti-TB drugs for all
TB patients including second-line drugs [25]. Eleven of 25 central and provincial hospitals pro-
vide both integrated TB and HIV services, including the provision of both TB treatment and
Anti-Retroviral Therapy (ART) [26–28].
Study design, population, and sample size
Following the WHO recommended study design, we conducted a facility-based cross-sec-
tional survey and extrapolated costs in the patient’s current TB treatment phase (i.e. inten-
sive or continuation) to assess the total costs associated with a diagnosis of TB and ongoing
TB care [12]. We used a cluster sampling strategy to ensure a nationally representative sam-
ple. The primary sampling unit was the Basic Management Unit (BMU) of the NTP; these
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are 165 district, provincial, and central hospitals [1, 12]. A total of 25 BMUs was randomly
selected by a probability proportional to size (PPS) method applying the TB case notifica-
tion in 2017 for each BMU [1]. With a design effect of 2.0, an estimated catastrophic cost
prevalence of 50%, and a precision level of 5%, the required sample size was 725. We
assumed incidence of 50% catastrophic costs in Lao PDR from the previous TB patient cost
surveys conducted in the Western Pacific Region (Philippines: 35%, Vietnam: 63%, Mongo-
lia: 70% with an unweighted average of 56%) [29]. An estimated prevalence of 50% provided
the most conservative sample size. In addition to this nationally representative sample, we
enrolled additional and operationally feasible quotas of 120 TB-HIV co-infected patients
and 30 DR-TB (i.e. MDR-TB or RR-TB) patients to assess the difference in the financial
burden of TB comparing drug-resistant and drug-susceptible TB patients and for patients
with and without TB-HIV co-infection. We enrolled all the patients on DR-TB treatment at
the time of interview in the country (total sampling). For TB-HIV patients, assuming esti-
mated proportion of catastrophic costs at 80% with 10% precision and design effect of 2, the
sample size was estimated at 122.
All eligible TB patients were those who were currently on TB treatment linked to the NTP
(including adults and children) who had received at least 14 days of treatment in either the
intensive or continuation phase of TB treatment. The participants were selected randomly
from TB log-book at each facility. If a child was recruited, we interviewed the parent of the
child participant. We excluded people who were treated in facilities that are unlinked to the
NTP (i.e. private facilities which do not report TB cases to the NTP).
Data collection
We used a standardised questionnaire developed by WHO, adapted this to the country con-
text, and translated into the local language. Twelve interviewers were recruited through an
open recruitment process. We conducted a 3-day training for all staff and interviewers
involved in the survey in October 2018, and the interview tool was piloted during the training
using the Ona online platform [30]. We then undertook face-to-face interviews with randomly
selected TB patients at health facilities during their facility visits and entered responses directly
into tablets using the ONA online platform [12, 30].
The questionnaire included questions on different types of direct medical costs (e.g.
medical consultation, laboratory tests, medications, hospitalization), direct non-medical
costs (e.g. transportation, food, accommodation, and nutritional supplements such as vita-
min supplements and/or additional foods other than regular diets) and indirect costs
(income loss and time lost for care seeking). We also collected demographic and clinical
information, information on health care utilization, household assets, coping mechanisms
(e.g. dissaving, borrowing, sold assets), and perceived social and financial impacts of a TB
diagnosis and care. Each patient was interviewed once and reported on expenditures and
time spent for care seeking, coping mechanism, and household assets and income during
the current treatment phase (e.g. either the intensive phase or the continuation phase).
Total time spent for care seeking was estimated by multiplying time loss for the last visit
with frequency of visits per month and the duration of TB treatment. For patients inter-
viewed in the intensive phase, retrospective data on costs and time spent for care seeking
before TB diagnosis were also collected, however these questions were not asked of patients
in the continuation phase. Data collection was conducted between December 2018 until
January 2019, followed by the additional data collection for DR-TB and TB-HIV co-infected
patients which was carried out in May and June 2019.
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Data analysis
For continuous data, median, mean, inter-quartile range (IQR), 95% confidence interval (95%
CI) were presented, and for categorical data, frequencies were calculated. The median values
were used to present information on costs and incomes, due to the skewness of the data. We
assessed the difference between DS-TB and DR-TB using Fisher’s exact test for categorical
data and the Welsh T-test or two-sample Wilcoxon rank-sum test for continuous data. Statisti-
cal significance was defined as p<0.05, and statistical analyses and data visualizations were
performed using Stata 15.2 (StataCorp 2018) and R4.0.2 (CRAN: Comprehensive R Archive
Network at https://cran.r-project.org/). Due to different sampling methods for nationally rep-
resentative sample and additional sample of DR-TB and TB-HIV coinfected patients, statistical
tests were performed only in nationally representative sample. All cost and income data were
collected in the local currency (Lao Kip) and then were converted into US$ for analysis at the
rate of 8,495 Kip per 1 US$ (oanda.com).
For patient cost data, we calculated median costs with IQR stratified by different cost types
(direct medical and direct non-medical costs and indirect costs) from the time of onset of TB
symptom until the TB treatment completion. Since we collected only the costs of TB treatment
incurred during the treatment phase patients were in at the time of the interview, the costs of
the other treatment phase for were extrapolated based on the median costs incurred by other
patients in that treatment phase at the time of the interview. For example, to estimate pre-treat-
ment costs and costs during TB intensive phase for patients who were in continuation phase at
the time of interview, the median costs of pre-treatment costs and intensive phase were taken
from the patients who were in intensive phase at the time of interview. In this calculation for
extrapolating costs, costs from DS-TB and DR-TB patients, and patients with and without hos-
pitalizations were considered separately. We estimated income loss in TB patients’ households
using the income prior to the current TB episode and that at the time of interview (output
approach). Monthly self-reported income was used as the primary method for determining
household income. However, we also computed predicted annual household income based on a
linear regression analysis using household asset information (as we collected information on
household assets in the questionnaire). 20% of annual household income was used as the thresh-
old to define catastrophic costs due to TB, consistent with the definition proposed by WHO
[12]. Clustering effects associated with sampling method were adjusted in estimating overall
proportion of catastrophic costs using the svy command in Stata software. An additional sensi-
tivity analysis was conducted to assess how varying the threshold (to different percentages from
0% to 100%) affected the proportion of catastrophic costs faced by TB-affected households.
Then we carried out a univariate logistic regression analysis to identify demographic and
clinical factors associated with facing catastrophic costs due to TB. The sample used in this
regression excluded the additional patients recruited who had MDR-TB and TB-HIV co-infec-
tion. We included variables in our multivariate logistic regression analysis, if they were signifi-
cant at the 10% level (P<0.10) in univariate analyses. Clustering effects associated with
sampling method were adjusted both in univariate and multivariate analyses using the svy
command in Stata software.
Ethical approval
The survey was approved by the Ethics Review Committee of the WHO Regional Office for the
Western Pacific (WHO/WPRO) (Ref: 2018.10.LAO.4.STB) and the Lao PDR National Ethics
Committee for Health Research (Ref: 091/NECHR). Written informed consent was obtained
from all the survey participants before the commencement of the interview. For participants
aged< 15 years of age, we obtained written informed consent from a parent or guardian.
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Results
Study population
A total of 848 TB patients participated in the survey, and of these 725 patients (717 DS-TB and
8 DR-TB) were enrolled as a nationally representative sample (the national sample) and 123
patients (22 DR-TB and 101 TB-HIV) were enrolled as an additional sample (Table 1). In the
national sample, 59.7% were male, and the mean age was 50.4 years. 0.8% were children aged
under 15 years old. The proportion of HIV positive patients was 2.6%, while 32.0% had
unknown HIV status. The demographic characteristics of the national sample were similar to
the data observed and reported in NTP routine surveillance. The proportion of participants
with no education or had only attended primary school was 41.2%, and 61.9% had informal
paid jobs before their TB diagnosis. The majority of participants (75.9%, N = 550) reported
that they were not covered by any health insurance, and only (6.2%, N = 45) were insured by
Table 1. Socio-demographic characteristics of participants of the national TB patient cost survey by drug resistance and HIV status, Lao PDR, 2018–2019.
Characteristics Nationally representative sample With additional sample
DS-TB DR-TB P-value All All DR-TB All TB-HIV
n = 717 n = 8 n = 725 n = 30 n = 123
Gender Female 291 (40.6%) 1 (12.5%) 0.153 292 (40.3%) 14 (46.7%) 40 (32.5%)
Male 426 (59.4%) 7 (87.5%) 433 (59.7%) 16 (53.3%) 83 (67.5%)
Age mean (95%CI) 50.5 (49.3–
51.7)
41.4 (27.3–
55.4)
0.125 50.4 (49.2–
51.6)
44.7 (38.6–
50.8)
33.8 (32.0–
35.7)
HIV status Negative 466 (65.0%) 8 (100.0%) 0.103 474 (65.4%) 27 (90.0%) 0 (0.0%)
Positive 19 (2.6%) 0 (0.0%) 19 (2.6%) 2 (6.7%) 123 (100.0%)
Unknown 232 (32.4%) 0 (0.0%) 232 (32.0%) 1 (3.3%) 0 (0.0%)
Patient’s education
level
No education 177 (24.7%) 0 (0.0%) 0.136 177 (24.4%) 7 (23.3%) 5 (4.1%)
Primary school 265 (37.0%) 2 (25.0%) 267 (36.8%) 11 (36.7%) 34 (27.6%)
Secondary/High school 181 (25.2%) 5 (62.5%) 186 (25.7%) 8 (26.7%) 63 (51.2%)
Vocational, University and higher 73 (10.2%) 1 (12.5%) 74 (10.2%) 4 (13.3%) 14 (11.4%)
Other 21 (2.9%) 0 (0.0%) 21 (2.9%) 0 (0.0%) 6 (4.9%)
Occupation (pre-
disease)
Not employed 122 (17.0%) 0 (0.0%) 0.245 122 (16.8%) 2 (6.7%) 5 (4.1%)
Employed (formal) 78 (10.9%) 0 (0.0%) 78 (10.8%) 3 (10.0%) 30 (24.4%)
Employed (informal) 443 (61.8%) 6 (75.0%) 449 (61.9%) 20 (66.7%) 77 (62.6%)
Retired/student/housework 70 (9.8%) 2 (25.0%) 72 (9.9%) 5 (16.7%) 7 (5.7%)
Other 4 (0.6%) 0 (0.0%) 4 (0.6%) 0 (0.0%) 3 (2.4%)
Insurance type None 543 (75.7%) 7 (87.5%) 1.000 550 (75.9%) 26 (86.7%) 99 (80.5%)
National Health Insurance (NHI) 32 (4.5%) 0 (0.0%) 32 (4.4%) 2 (6.7%) 6 (4.9%)
Community-Based Health Insurance
(CBHI)
81 (11.3%) 1 (12.5%) 82 (11.3%) 1 (3.3%) 0 (0.0%)
Health Equity Fund (HEF) 6 (0.8%) 0 (0.0%) 6 (0.8%) 0 (0.0%) 3 (2.4%)
Social Security Organization (SSO) 3 (0.4%) 0 (0.0%) 3 (0.4%) 0 (0.0%) 4 (3.3%)
State Authority for Social Security
(SASS)
42 (5.9%) 0 (0.0%) 42 (5.8%) 1 (3.3%) 5 (4.1%)
Private health insurance 10 (1.4%) 0 (0.0%) 10 (1.4%) 0 (0.0%) 2 (1.6%)
Other 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 3 (2.4%)
Household size mean (95%CI) 5.7 (5.5–5.9) 4.5 (3.7–5.3) 0.170 5.7 (5.5–5.9) 4.6 (3.8–5.4) 4.4 (4.1–4.7)
Monthly household
income
median (IQR), in US$ 235 (118–471) 235 (141–347) 0.726 235 (118–471) 235 (118–494) 353 (200–589)
IQR: Interquartile range, 95% CI: 95% confidence interval, DS-TB: drug-susceptible TB, DR-TB: drug-resistant TB.
https://doi.org/10.1371/journal.pone.0241862.t001
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SSO or SASS. The mean household size was 5.7 individuals with a median monthly household
income of US$ 235 (IQR: 118–471).
No significant differences were observed in socio-demographic factors when comparing
patients with DS-TB from the national sample and patients with DR-TB. In all TB-HIV
patients with additional sample (N = 123), the mean age of 33.8 years was considerably lower
than the nationally representative sample (the mean age of 50.4 years), and the median
monthly household income of US$ 353 was higher than other groups (Table 1).
In the national sample, 97.9% were newly diagnosed, and 62.8% were in the continuation
phase of TB treatment (Table 2). The majority (94.2%) had pulmonary TB, and 68.2% were
bacteriologically confirmed. The proportion of patients who were taking TB treatment in a
public health centre or a district hospital was 71.0% in the national sample. On the other hand,
most of the DR-TB and TB-HIV coinfected patients were receiving TB treatment in provincial
or central hospitals (DR-TB: 100% and TB-HIV: 96.7%) with a high incidence of hospitaliza-
tion during the current treatment phase compared to patients with DS-TB (national sample
DR-TB: 75.0% and DS-TB: 11.4% p<0.001. With additional samples, all DR-TB: 90.0% and all
TB-HIV: 38.2%).
The median number of weeks reported from the onset of TB symptoms until initiation of
TB treatment was 4 weeks, with an average of 1.8 visits to a health facility before a TB diagnosis
was made (the maximum number of visits was 19). Just over one third (30.4%, N = 79) of 260
patients who were in the intensive phase initiated their care seeking at private healthcare pro-
viders such as traditional healers, private pharmacies, clinics and/or hospitals. The large major-
ity of patients in the national sample (97.7%) were self-administering TB medications, while
half of DR-TB patients were receiving directly observed therapy (DOT) while they were hospi-
talized in the TB ward (national sample, DS-TB: 1.8%, DR-TB: 50.0%, p<0.001. With addi-
tional sample, all DR-TB: 56.7%, all TB-HIV: 12.2%). Therefore, visits for drug pick-up was
most frequent (15.6 times) in the national sample and for patients with DS-TB, while DR-TB
patients had more DOT visits (136.4 times) during TB treatment.
Time loss for care seeking
The median total time loss for care seeking for TB patients and their caregivers from the onset
of TB symptoms until the completion of TB treatment was 95 hours (IQR: 79–139) and 1 hour
(IQR: 0–13), respectively, with a significantly larger time loss for DR-TB patients when com-
pared to DS-TB patients in the national sample (patients: DS-TB 95 hours (IQR: 79–139),
DR-TB 1,327 hours (IQR: 665–2,517), p = 0.006) (Table 3). Time loss associated with the pre-
diagnosis period and hospitalization was also significantly longer among DR-TB patients com-
pared to DS-TB (Pre-diagnosis: DS-TB 9 hours (IQR: 3–44), DR-TB 40 hours (IQR: 32–270),
p = 0.050. Hospitalization: DS-TB 76 hours (IQR: 37–158), DR-TB 755 hours (IQR: 301–
1,088), p = 0.026). No significant differences were observed in time loss in caregivers in the
national sample. With additional sample, TB-HIV patients also reported a considerably longer
time spent on hospitalization (patients: 122 hours (IQR: 83–220)).
Estimated total costs borne by TB patient and their households
The total median cost incurred for TB care was US$ 755 (IQR: US$ 351–1,454); equivalent to
3.2 times the average monthly salary of TB patients in the survey (Table 4). Only 9.2% of costs
were incurred before a TB diagnosis. The largest cost driver was direct non-medical costs
(46.6%), followed by indirect costs (37.6%) and direct medical costs (15.8%) (Fig 1). In partic-
ular, the costs for special foods and nutritional supplements other than the patients regular
diet was high, comprising 34.8% of total costs. Total costs were nearly double for TB-HIV co-
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infected patients and triple for patients with DR-TB (DR-TB: US$ 2,243, TB-HIV: US$ 1,633)
compared to DS-TB patients (US$ 748). The high costs among DR-TB and TB-HIV co-
infected patients were largely attributed to nutritional supplements outside their normal diet
and income loss during TB treatment, while TB-HIV co-infected patients had a relatively large
proportion of direct medical costs (DR-TB: nutritional supplement 49.7%, income loss 35.1%)
(TB-HIV: nutritional supplement 23.3%, income loss 39.2%, direct medical costs 26.2%) (Fig
1).
Table 2. Clinical characteristics of participants of the national TB patients cost survey by drug resistance and HIV status, Lao PDR, 2018–2019.
Characteristics Nationally representative sample With additional sample
DS-TB DR-TB P-value All All DR-TB All TB-HIV
n = 717 n = 8 n = 725 n = 30 n = 123
Treatment phase Intensive phase 265 (37.0%) 5 (62.5%) 0.156 270 (37.2%) 19 (63.3%) 50 (40.7%)
Continuation phase 452 (63.0%) 3 (37.5%) 455 (62.8%) 11 (36.7%) 73 (59.3%)
Treatment category New 702 (97.9%) 8 (100.0%) 1.000 710 (97.9%) 24 (80.0%) 121 (98.4%)
Relapse 12 (1.7%) 0 (0.0%) 12 (1.7%) 2 (6.7%) 0 (0.0%)
Loss to follow-up or
treatment after failure
2 (0.3%) 0 (0.0%) 2 (0.3%) 4 (13.3%) 1 (0.8%)
Type and diagnosis of TB Pulmonary TB
(Bacteriologically
Confirmed)
488 (68.1%) 7 (87.5%) 0.646 495 (68.3%) 28 (93.3%) 42 (34.1%)
Pulmonary TB (Clinically
diagnosed)
191 (26.6%) 1 (12.5%) 192 (26.5%) 2 (6.7%) 67 (54.5%)
Extra pulmonary TB 38 (5.3%) 0 (0.0%) 38 (5.2%) 0 (0.0%) 14 (11.4%)
Planned treatment
duration
6 months 715 (97.7%) 0 (0.0%) <0.001��� 715 (98.6%) 0 (0.0%) 123 (100.0%)
9 months 0 (0.0%) 8 (100.0%) 8 (1.1%) 30 (100.0%) 0 (0.0%)
12 months 2 (0.3%) 0 (0.0%) 2 (0.3%) 0 (0.0%) 0 (0.0%)
Registered facility type Public health centre 133 (18.5%) 0 (0.0%) 0.136 133 (18.3%) 0 (0.0%) 0 (0.0%)
District hospital 382 (53.3%) 0 (0.0%) 382 (52.7%) 0 (0.0%) 4 (3.3%)
Provincial hospital 134 (18.7%) 4 (50.0%) 138 (19.0%) 12 (40.0%) 56 (45.5%)
Central, military or police
hospital
68 (9.5%) 4 (50.0%) 72 (9.9%) 18 (60.0%) 63 (51.2%)
From onset of symptom
until diagnosis
median (IQR), in weeks 4 (2–7) 8 (2–8) 0.672 4 (2–8) 2 (1–8) 2 (1–4)
Hospitalization Hospitalized at time of
interview
7 (1.0%) 6 (75.0%) <0.001��� 13 (1.8%) 27 (90.0%) 9 (7.3%)
Hospitalized (current
phase)
82 (11.4%) 6 (75.0%) <0.001��� 88 (12.1%) 27 (90.0%) 47 (38.2%)
Times hospitalized (current
phase)
1.3 (1.1–1.5) 1.0 (1.0–1.0) 0.449 1.3 (1.1–1.4) 1.0 (0.9–1.1) 1.2 (1.1–1.3)
Mode of TB treatment Self administered 704 (98.2%) 4 (50.0%) <0.001��� 708 (97.7%) 13 (43.3%) 107 (87.0%)
Directly observed therapy 13 (1.8%) 4 (50.0%) <0.001��� 17 (2.3%) 17 (56.7%) 15 (12.2%)
Number of health facility
visits, mean (95%CI)
Pre-disease 1.8 (1.6–2.1) 2.4 (0.3–4.5) 0.498 1.8 (1.6–2.1) 1.8 (1.1–2.6) 1.5 (1.2–1.9)
Directly observed therapy 2.6 (1.1–4.1) 136.4 (14.5–258.3) <0.001��� 4.1 (2.0–6.2) 137.1 (85.8–188.4) 18.6 (8.9–28.3)
Drug pick-up 16.1 (15.0–
17.2)
15.8 (11.4–20.3) 0.962 15.6 (14.8–
16.3)
18.7 (17.4–20.0) 12.6 (10.5–
14.7)
Follow-up 2.4 (2.0–2.8) 0.2 (-0.3–0.6) 0.274 2.4 (2.0–2.8) 0.8 (-0.4–2.0) 1.6 (0.8–2.5)
� Significant difference (0.01� p < 0.05).
�� Significant difference (0.001� p < 0.01).
��� Significant difference (p < 0.001).
IQR: Interquartile range, 95% CI: 95% confidence interval, DS-TB: drug-susceptible TB, DR-TB: drug-resistant TB.
https://doi.org/10.1371/journal.pone.0241862.t002
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Reported coping mechanisms and social consequences
In the national sample, half (49.9%) of households relied on savings, loans, and/or selling assets
to cope with the financial burden and consequences of TB (Table 5), while this figure was
higher for DR-TB patients (56.7%) and TB-HIV co-infected patients (65.0%). One fifth
(N = 147, 20.3%) of households experienced food insecurity, 29.5% lost a job, and 10.3% expe-
rienced social exclusion due to TB. The proportion of TB-affected households who experi-
enced separation or divorce from their partners or who had interrupted schooling for their
children was significantly higher among DR-TB patients (separation/divorce: DS-TB 2.1%,
DR-TB 12.5%, p = 0.046) (interrupted schooling: DS-TB 1.4%, DR-TB 12.5%, p = 0.011).
More than half of the national sample (54.5%) reported that TB care had a moderate, severe,
or very severe financial impact on their household, and 56.3% perceived that TB treatment
impoverished their households, when compared to their baseline financial position (Table 6).
These proportions were significantly higher among DR-TB patients in the national sample
(financial impact: DS-TB 54.2%, DR-TB 87.5%, p = 0.002. Impoverishment: DS-TB 56.0%,
DR-TB 87.5%, p = 0.026).
The proportion of patients who became unemployed more than doubled when comparing
the baseline situation to the situation at the time of interview (16.8% to 35.4%), while the pro-
portion of employment in the informal sector decreased from 61.9% to 43.6% (Fig 2). The pro-
portion of formal employment decreased from 10.8% to 8.8% when comparing the same time
periods. Only one (0.1%) of the national sample utilized sick leave, and four (0.4%) received
social welfare, including an unemployment benefit. Among DR-TB patients, who were eligible
to receive support for food and transportation from the NTP, only three (10.0%) reported that
they received these TB specific financial supports.
Proportion of households facing catastrophic costs
In the national sample, the proportion of TB affected households facing catastrophic costs was
62.6% (95% CI 57.6%-67.3%) at the threshold at 20% of annual household income. With
Table 3. Time loss for TB care seeking in participants of the national TB patients cost survey by drug resistance and HIV status, Lao PDR, 2018–2019.
Time loss due to TB (working hour basis) Nationally representative sample With additional sample
DS-TB DR-TB P-value All All DR-TB All TB-HIV
n = 717 n = 8 n = 725 n = 30 n = 123
Hours lost by patient, median
(IQR)
Overall 95 (79–139) 1,327 (665–2,517) 0.006�� 95 (79–139) 1,418 (1,219–2,194) 122 (83–220)
Pre-diagnosis 9 (3–44) 40 (32–270) 0.050� 10 (3–47) 10 (4–40) 24 (6–53)
Hospitalization 76 (37–158) 755 (301–1,088) 0.026� 78 (38–165) 858 (694–1,088) 185 (66–453)
Directly observed
therapy
65 (30–130) 39 (27–45) 0.306 45 (30–65) 23 (23–45) 15 (4–30)
Drug pick-up 9 (4–17) 2 (1–10) 0.023� 9 (4–17) 2 (1–3) 13 (6–26)
Follow-up 1 (0–4) 0 (0–4) 0.291 1 (0–4) 0 (0–0) 0 (0–0)
Hours lost by caregiver, median
(IQR)
Overall 1 (0–13) 2 (0–301) 0.616 1 (0–13) 0 (0–0) 0 (0–52)
Hospitalization 102 (39–206) 541 (61–1,209) 0.185 104 (42–305) 964 (541–1,789) 337 (68–765)
Directly observed
therapy
39 (0–130) 45 (45–45) 0.826 42 (15–97) 45 (45–45) 15 (7–30)
Drug pick-up 13 (5–26) 21 (3–39) 0.935 13 (6–26) 21 (3–39) 13 (6–26)
Follow-up 1 (0–21) 0 (0–0) 0.301 1 (0–21) 0 (0–0) 0 (0–0)
� Significant difference (0.01� p < 0.05).
�� Significant difference (0.001� p < 0.01).
IQR: Interquartile range, DS-TB: drug-susceptible TB, DR-TB: drug-resistant TB.
https://doi.org/10.1371/journal.pone.0241862.t003
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additional sample, the proportion of DR-TB and TB-HIV coinfected patients who experienced
catastrophic costs was substantially higher than DS-TB patients; DS-TB: 62.3% (95%CI: 57.4%
- 67.0%), DR-TB: 86.9% (73.8% - 99.6%), and TB-HIV: 81.1% (95%CI: 74.1% - 88.2%) (Fig 3).
The overall incidence of catastrophic costs ranged from 47.3% to 82.2% when changing the
threshold from 10% to 30% of annual household income (Fig 4).
Risk factors for households experiencing catastrophic costs
After adjusting for potential confounders and covariates, wealth quintile was the only factor
which was associated with the probability of incurring catastrophic costs in multivariate analy-
ses (Table 7). Households in lower wealth quintiles had a significantly higher incidence of fac-
ing catastrophic costs compared to those in the highest wealth quintile (Lowest wealth
quintile: 90.6%, OR = 28.8, p<0.001. 2nd lowest wealth quintile: 73.1%, OR = 6.0, p<0.001.
Middle wealth quintile: 56.9%, OR = 3.0, p<0.001. 2nd highest wealth quintile: 53.0%,
OR = 2.7, p = 0.001. Highest wealth quintile (Ref): 27.5%).
Table 4. Estimated median total costs incurred by TB-affected households in Lao PDR, 2018–2019, assessed by output approach (in US$).
TB patient costs Nationally representative sample With additional sample
DS-TB DR-TB All All DR-TB All TB-HIV
median (IQR) median (IQR) median (IQR) median (IQR) median (IQR)
n = 717 n = 8 n = 725 n = 30 n = 123
Pre-TB
diagnosis
Direct medical Total 40 (6–177) 71 (24–73) 41 (6–177) 71 (24–106) 138 (35–353)
Hospitalization 4 (0–31) 6 (1–17) 4 (0–29) 2 (0–11) 99 (8–353)
Outpatient services 38 (7–174) 71 (13–186) 38 (7–174) 71 (21–212) 87 (12–239)
Direct non-
medical
Total 11 (4–39) 40 (24–52) 11 (4–39) 15 (9–52) 17 (8–79)
Travel 4 (1–12) 7 (4–24) 4 (1–12) 9 (2–13) 5 (1–12)
Food 1 (0–8) 8 (0–26) 1 (0–8) 1 (0–5) 2 (0–6)
Accommodation 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0)
Post-TB
diagnosis
Direct medical Total 27 (13–30) 210 (145–479) 29 (13–30) 0 (0–83) 261 (15–282)
Hospitalization 13 (13–30) 208 (111–381) 13 (13–30) 0 (0–15) 261 (15–261)
Directly observed
therapy
0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0)
Drug pick-up 0 (0–31) 132 (69–195) 0 (0–31) 69 (0–195) 27 (8–54)
Follow-up 0 (0–3) 0 (0–2) 0 (0–3) 0 (0–0) 0 (0–0)
Direct non-
medical
Total 327 (169–702) 266 (209–791) 327 (173–703) 863 (410–1,276) 680 (474–991)
Travel 33 (18–62) 85 (78–201) 33 (18–64) 50 (50–64) 64 (33–125)
Food 0 (0–31) 25 (18–154) 1 (0–31) 11 (9–58) 23 (12–55)
Accommodation 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0) 0 (0–0)
Nutritional Supplement 229 (104–581) 161 (115–210) 223 (104–566) 275 (183–1,009) 367 (229–612)
Other 0 (0–15) 10 (0–46) 0 (0–15) 0 (0–14) 0 (0–15)
Indirect costs (output approach) 32 (0–565) 1,324 (318–1,881) 57 (0–565) 795 (0–1,589) 512 (0–1,059)
Total direct medical costs 53 (53–88) 280 (167–526) 53 (53–88) 71 (21–129) 261 (60–440)
Total direct non-medical costs 338 (185–735) 298 (226–816) 338 (186–736) 868 (464–1,276) 696 (481–1,065)
Total indirect costs 32 (0–565) 1,324 (318–1,881) 57 (0–565) 795 (0–1,589) 512 (0–1,059)
Total TB patient costs 748 (350–
1,432)
2,205 (1,081–
3,273)
755 (351–
1,454)
2,243 (1,231–
2,986)
1,633 (1,007–
2,653)
IQR: Interquartile range, DS-TB: drug-susceptible TB, DR-TB: drug-resistant TB.
https://doi.org/10.1371/journal.pone.0241862.t004
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Discussion
This survey was the first national TB patient cost survey in Lao PDR. It assessed the magnitude
and the main drivers of costs faced by TB patients and their households, designed to aid in the
development of policies and interventions to reduce the financial barriers associated with TB
care. This survey also establishes a baseline against which to monitor progress towards the
elimination of catastrophic costs due to TB in Lao PDR, aligned to the targets in their National
TB Strategic Plan and the End TB Strategy [11, 12].
Although free TB services are provided in public health facilities in Lao PDR, 62.2% of
DS-TB, 86.7% of DR-TB, and 81.1% of TB-HIV co-infected patients incurred catastrophic
costs. A TB diagnosis and care cost households US$ 755 which was equivalent to more than 3
times the average monthly salary of TB patients in the survey. The main cost driver was direct
non-medical costs followed by income loss. To cope with the economic burden, half (49.9%)
of patients had to rely on savings (21.4%), borrowing money (26.3%) or selling assets (17.7%),
Fig 1. Composition of TB patient costs in Lao PDR, by drug resistance and HIV status, 2018–2019.
https://doi.org/10.1371/journal.pone.0241862.g001
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which has the potential to cause prolonged negative impacts on their lives [31]. The key find-
ings of this survey will contribute to open the doors for effective policy dialogues at the
national level with multisectoral partners to improve TB service delivery and financing to
reduce financial burden due to TB. As of July 2019, 14 countries including Lao PDR had com-
pleted a national TB patient cost survey and of those, 8 countries are in Asia (China, Fiji, Lao
PDR, Mongolia, Myanmar, Philippines, Timor-Leste, Viet Nam). The proportion of TB-
affected households who faced catastrophic costs in this survey was similar to the figures in
Mongolia (68%), Myanmar (60%) and Vietnam (63%) [1, 32]. In our survey, a high proportion
of catastrophic costs was reported from DR-TB patients and their households, which is consis-
tent with the results from other countries (ranging from 67% to 100%). Similar to the Lao PDR
survey, the main contributor to total patient costs was direct non-medical costs in Fiji and Viet
Table 5. Reported coping mechanisms and social consequences in participants of the national TB patients cost survey by drug resistance and HIV status, Lao PDR,
2018–2019.
Coping mechanism and social consequences Nationally representative sample With additional sample
DS-TB DR-TB P-value All All DR-TB All TB-HIV
n = 717 n = 8 n = 725 n = 30 n = 123
Coping strategy Dissaving 152 (21.2%) 3 (37.5%) 0.706 155 (21.4%) 14 (46.7%) 59 (48.0%)
Loan 189 (26.4%) 2 (25.0%) 0.610 191 (26.3%) 7 (23.3%) 43 (35.0%)
Sale of assets 127 (17.7%) 1 (12.5%) 1.000 128 (17.7%) 3 (10.0%) 22 (17.9%)
Any of above 358 (49.9%) 4 (50.0%) 0.088 362 (49.9%) 17 (56.7%) 80 (65.0%)
Social effect Food insecurity 146 (20.4%) 1 (12.5%) 0.582 147 (20.3%) 3 (10.0%) 13 (10.6%)
Divorce/separation 15 (2.1%) 1 (12.5%) 0.046� 16 (2.2%) 3 (10.0%) 2 (1.6%)
Job loss 212 (29.6%) 2 (25.0%) 0.778 214 (29.5%) 12 (40.0%) 58 (47.2%)
Interrupted schooling 10 (1.4%) 1 (12.5%) 0.011� 11 (1.5%) 1 (3.3%) 5 (4.1%)
Social exclusion 73 (10.2%) 2 (25.0%) 0.171 75 (10.3%) 5 (16.7%) 10 (8.1%)
Any of above 419 (58.4%) 6 (75.0%) 0.344 425 (58.6%) 19 (63.3%) 76 (61.8%)
� Significant difference (0.01� p < 0.05).
DS-TB: drug-susceptible TB, DR-TB: drug-resistant TB.
https://doi.org/10.1371/journal.pone.0241862.t005
Table 6. Perceived financial impact and impoverishment in participants of the national TB patients cost survey by drug resistance and HIV status, Lao PDR, 2018–
2019.
Perceived financial impact and impoverishment Nationally representative sample With additional sample
DS-TB DR-TB P-value All All DR-TB All TB-HIV
n = 717 n = 8 n = 725 n = 30 n = 123
Self-reported financial impact No impact 79 (11.0%) 1 (12.5%) 0.002�� 80 (11.0%) 4 (13.3%) 12 (9.8%)
Little impact 250 (34.9%) 250 (34.5%) 4 (13.3%) 30 (24.4%)
Moderate impact 222 (31.0%) 1 (12.5%) 223 (30.8%) 9 (30.0%) 30 (24.4%)
Serious impact 144 (20.1%) 4 (50.0%) 148 (20.4%) 10 (33.3%) 41 (33.3%)
Very serious impact 22 (3.1%) 2 (25.0%) 24 (3.3%) 3 (10.0%) 9 (7.3%)
Self-reported impoverishment Richer 0 (0.0%) 0 (0.0%) 0.026� 0 (0.0%) 0 (0.0%) 0 (0.0%)
Unchanged 316 (44.1%) 1 (12.5%) 317 (43.7%) 11 (36.7%) 56 (45.5%)
Poorer 369 (51.5%) 5 (62.5%) 374 (51.6%) 13 (43.3%) 52 (42.3%)
Much poorer 32 (4.5%) 2 (25.0%) 34 (4.7%) 6 (20.0%) 14 (11.4%)
� Significant difference (0.01� p < 0.05).
�� Significant difference (0.001� p < 0.01).
DS-TB: drug-susceptible TB, DR-TB: drug-resistant TB
https://doi.org/10.1371/journal.pone.0241862.t006
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Nam. The survey in Lao PDR was the first national survey to assess costs and catastrophic
costs among TB-HIV co-infected patients, and the proportion of TB-affected households who
faced catastrophic costs was as high as that of DR-TB. This result has highlighted the necessity
to assess patient costs in households with TB-HIV co-infected patients and to facilitate inter-
ventions to minimize the financial burden especially in countries with a high burden of
TB-HIV coinfection. Integrated services for TB and HIV was provided only at 11 of 25 central
and provincial hospitals, and therefore patients with TB-HIV coinfection had to travel to those
hospitals that are usually located far from their residences compared to public health centers
or district hospitals, or had to have separate facility visits for TB and HIV treatments [26–28].
Enhancing and decentralizing integrated services for TB and HIV would be necessary to miti-
gate the financial burden in TB-HIV coinfected patients.
Nutritional supplements other than the patient’s regular diet comprised (34.8%) of all direct
non-medical costs in Lao PDR. Malnutrition is a common clinical finding in TB patients and
also a risk factor for developing active TB [33, 34]. Due to a bi-directional association between
having TB and malnutrition, TB patients often lose their appetite and body weight when they
develop TB, and can then become malnourished due to metabolic changes during TB treat-
ment [35–37]. Patients and their households may believe or be advised that eating protein rich
foods enhances the effectiveness of TB treatment leading them to buy additional foods that
might lead TB-affected households to spend a relatively large amount on food or other nutri-
tional supplements [38]. In TB patient cost surveys in Kenya and Ghana, body mass index
(BMI) of the survey participants was calculated, and more than half of the participants in the
Fig 2. Changes of employment status: Before having TB and during TB treatment, in national sample (N = 725) of the national TB patients cost survey, Lao
PDR, 2018–2019.
https://doi.org/10.1371/journal.pone.0241862.g002
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survey were severely (BMI<16.5) or moderately (BMI<18.5) malnourished, and direct non-
medical costs were also a main cost driver as they were in Lao PDR [39]. The results in Kenya
and Ghana highlight the necessity to investigate the prevalence of malnutrition and the need
to enhance nutritional support for TB patients [39].
In Lao PDR, the NTP implements a cash transfer programme for DR-TB patients that pro-
vides US$ 5 per day to support expenses for food and transportation. However, only 10% of
the participants with DR-TB in this survey reported that they received such support. Similarly,
in Cambodia, an existing government scheme that provides poor people with transportation
and food costs associated with their health-seeking to public health facilities was largely under-
utilized [40]. Also, it is not known how this cash transfer programme in Lao PDR contributes
to TB patients’ nutritional recovery. Although WHO recommends systematic nutritional
assessment and counselling for TB patients [41], such services are not systematically provided
for TB patients in Lao PDR, and nutritional status such as weight, height, and BMI were not
investigated in this survey. The National Nutrition Strategy 2016–2020 prepared by the
National Nutrition Centre has a strategic objective to prevent TB related malnutrition by man-
aging and controlling acute malnutrition associated with TB [42]. Enhancing collaboration
Fig 3. Median total costs and proportion of households facing catastrophic costs due to TB using 20% threshold of annual household income by drug
resistance and HIV status. � Error bars show 95% confidence interval for proportion of catastrophic costs. �� Overall proportion of catastrophic costs were
adjusted for all variables in the final model as well as for clustering effects associated with sampling method.
https://doi.org/10.1371/journal.pone.0241862.g003
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between TB and nutrition programmes is imperative to have a better understanding of TB
patient’s nutritional status and to improve nutritional support for TB patients.
Although only 9.2% of total costs was incurred before TB diagnosis, this survey revealed
that TB patients needed to visit health facilities on average 1.8 times before they were diag-
nosed, with a median delay of 4 weeks from the onset of TB symptoms to diagnosis. 36% of TB
patients sought care at private facilities and half of them visited private facilities multiple times
before TB diagnosis. The treatment delay that we observed was in the range of results obtained
in other national TB patient cost surveys (0.14 weeks in Timor-Leste, 2.9 weeks in Kenya, 4
weeks in Ghana, 6.2 weeks in Viet Nam) [32, 39, 43, 44] Streamlining the TB patient pathway
by enhancing the referral system and improving linkages with the private sector at all facility
levels will likely minimize diagnostic delay and patient costs. Implementing active case finding
(ACF) may result in a shorter delay in TB diagnosis compared to facility based passive case
finding (PCF) as well as reduction in costs incurred by TB patients [45, 46]. A study in Cambo-
dia comparing TB patient costs between ACF and PCF revealed that costs before TB diagnosis
was significantly lower among patients detected with ACF compared to those with PCF
whereas no difference was found in costs during TB treatment [40]. Furthermore, increasing
awareness of the NHI would be also important to have early diagnosis of TB. Our study
Fig 4. Changing threshold to define proportion of TB-affected household experiencing catastrophic costs, with national sample (N = 725) of the national
TB patients cost survey, Lao PDR, 2018–2019.
https://doi.org/10.1371/journal.pone.0241862.g004
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Table 7. Factors associated with catastrophic costs faced by TB-affected households, Lao PDR, 2018–2019.
Risk factors Total Facing
catastrophic
costs
Univariate Multivariate
N % Crude
OR
95% CI p-value Adjusted
OR
95% CI p-value
Age in years - - - 0.99 (0.99–1.00) 0.184 - - -
Sex Female 292 187 (64.0%) Ref - - - - -
Male 433 266 (61.4%) 0.91 (0.64–1.29) 0.573 - - -
Insurance Any insurance 175 105 (60.0%) Ref - - - - -
No insurance 550 348 (63.3%) 1.14 (0.82–1.59) 0.415 - - -
Education Secondary or higher 281 162 (57.7%) Ref - - Ref - -
Primary school 177 118 (66.7%) 1.42 (0.87–2.31) 0.153 0.80 (0.40–1.62) 0.527
No education 267 173 (64.8%) 1.38 (0.95–1.99) 0.088 0.93 (0.55–1.56) 0.765
Occupation Employed (formal) 78 36 (46.2%) Ref - - Ref - -
Unemployed 122 72 (59.0%) 1.71 (0.91–3.23) 0.091 0.95 (0.49–1.85) 0.870
Employed (informal) 449 316 (70.4%) 2.73 (1.70–4.39) <0.001��� 1.66 (0.96–2.87) 0.066
Other (housework, student etc) 76 29 (38.2%) 0.74 (0.41–1.34) 0.307 0.60 (0.31–1.16) 0.122
Household income
quintile
Highest 91 25 (27.5%) Ref - - Ref - -
Second highest 149 79 (53.0%) 3.06 (1.78–5.26) <0.001��� 2.66 (1.56–4.52) 0.001��
Middle 195 111 (56.9%) 3.47 (1.94–6.18) <0.001��� 2.98 (1.72–5.17) <0.001���
Second lowest 141 103 (73.0%) 7.03 (3.37–
14.65)
<0.001��� 5.99 (2.84–
12.61)
<0.001���
Lowest 149 135 (90.6%) 29.28 (13.37–
64.13)
<0.001��� 28.79 (11.57–
71.64)
<0.001���
Household size - - - 0.95 (0.89–1.01) 0.084 0.96 (0.89–1.04) 0.273
Treatment phase Intensive phase 270 179 (66.3%) Ref - - - - -
Continuation phase 455 274 (60.2%) 0.76 (0.51–1.14) 0.175 - - -
Drug susceptibility Drug susceptible TB 717 446 (62.2%) Ref - - Ref - -
Drug resistant TB 8 7 (87.5%) 4.02 (0.47–
34.56)
0.194 3.89 (0.57–
26.29)
0.156
Treatment category New 710 444 (62.5%) Ref - - - - -
Relapse 12 8 (66.7%) 1.34 (0.32–5.59) 0.680 - - -
Loss to follow-up or Treatment
after failure
2 1 (50.0%) 0.53 (0.03–
10.28)
0.665 - - -
Delay in TB diagnosis 1 month or less 627 391 (62.4%) Ref - - - - -
More than 1 month 98 62 (63.3%) 1.05 (0.62–1.77) 0.859 - - -
HIV status Negative/unknown 706 440 (62.3%) Ref - - - - -
Positive 19 13 (68.4%) 1.38 (0.47–4.07) 0.546 - - -
Self reported financial
impact
No or little impact 330 163 (49.4%) Ref - - - - -
Moderate, serious, very serious
impact
395 290 (73.4%) 2.89 (1.96–4.28) <0.001��� - - -
Self reported
impoverishment
Richer/unchanged 317 145 (45.7%) Ref - - - - -
Poorer/much poorer 408 308 (75.5%) 3.66 (2.48–5.41) <0.001��� - - -
� Significant difference (0.01� p < 0.05)
�� Significant difference (0.001� p < 0.01)
��� Significant difference (p < 0.001)
95% CI: 95% confidence interval, OR: Odds Ratio
Crude ORs are adjusted for clustering effects associated with sampling method
Adjusted ORs are adjusted for all variables in the final model as well as for clustering effects associated with sampling method
https://doi.org/10.1371/journal.pone.0241862.t007
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showed a considerably low recognition of NHI coverage among TB patients (75.9% reported
no insurance) even though the NHI was implemented in 2016 (2 years back from the time of
this study). This low recognition of NHI could be a barrier to use healthcare services in public
facilities after having TB symptoms.
Currently, free TB services are provided in public health facilities in Lao PDR with financial
support from the Global Fund in addition to government funding, and therefore the direct
medical costs had a relatively smaller impact on total TB patient costs in this survey (15.8%).
Ensuring the future sustainability of free and high-quality TB services in this country is key to
minimize the delay in TB diagnosis and initiating TB treatment and to reduce the out-of-
pocket expenditure for the direct medical costs for TB.
The proportion of patients who were unemployed increased when comparing patient’s
employment status pre and post TB diagnosis. Patients who were working in the informal sec-
tor, which consisted of 61.9% of the survey population, were more likely to have lost their jobs,
and currently there is no unemployment protection scheme for those working in the informal
sector in Lao PDR. Implementing an additional cash transfer programme would be one option
to address this issue. In Vietnam, after conducting TB patient cost survey, the NTP imple-
mented an innovative financial support scheme, so called “Patients Support Foundation to
End Tuberculosis (PASTB)” for TB patients in poverty using a short message service (SMS)
[47]. In this campaign, every SMS will transfer US$0.8 to the foundation to provide financial
support for TB patients [47]. In addition to the financial supports during TB treatment, the
post-treatment socio-economic recovery (e.g. re-employment after TB treatment) is also
important to minimize long-term or permanent financial impacts due to TB. However, no
studies assessing long-term economic shocks in TB-affected households after completion of
TB treatment (e.g. permanent job loss, continuous social exclusion) are published yet except
for an on-going study in African countries [48]. Therefore, more evidences around post-treat-
ment economic impacts due to TB are required especially in Asian contexts. On the other
hand, TB patients who are employed in the formal sector are eligible for unemployment and
sickness benefits that are provided by NSSF. The sickness benefit covers 70% of the employee’s
salary in the first 6 months of sick leave, and the rate decreases to 60% after the first 6 months
[22]. However, only one TB patient in this survey received this sickness benefit. The current
claim mechanism requires TB patients or their household members to visit district or provin-
cial offices that are usually located far from the patient’s community. Re-designing the claim
mechanism in collaboration with NSSF may facilitate wider access to the sickness benefit, thus
minimizing TB patient costs.
In addition, the national HIV/AIDS Control and Prevention law implemented since 2010,
prohibits discrimination or stigmatization towards people living with HIV/AIDS, including
firing healthy HIV positive persons from their jobs [49]. There may be a need to explore col-
laboration with the labour and corporate sectors, as well as civil society, to investigate work-
place policies and to advocate for stronger legal frameworks such as enactment of a TB law,
with provisions to protect people with TB from being fired, such as the case with the HIV law.
This survey has several limitations. First, this survey was a cross-sectional study and the
estimated total costs were based on an extrapolation method [12]. Longitudinal methods
which incorporate information from multiple interviews with each patient over time may
reflect the true costs of TB illness, although this method would be more complex and lengthy.
Estimated costs incurred by TB patients and their households might be affected by recall bias if
only recalled once and when recalling costs that were incurred in the past. Also, some of the
total patient costs were extrapolated from the costs incurred by patients in the intensive phase
or those in continuation phase. This crude extrapolation method may result in over or under
estimation of costs and the overall incidence of catastrophic costs. Second, 123 additional
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patients (22 DR-TB patients and 101 TB-HIV coinfected patients) were enrolled with purpo-
sive sampling at different time (in May-June 2019) separately from the 725 nationally repre-
sentative sample (in December 2018-January 2019). Thus, statistical comparison between two
samples were not carried out for this reason. Furthermore, although we conducted statistical
tests comparing various factors between DS-TB and DR-TB patients in the national sample,
the number of DR-TB patients in the national sample was very few (N = 8) and not enough
especially for risk factor analysis for facing catastrophic costs. Third, study participants were
enrolled only from NTP engaged facilities. Therefore, costs incurred by patients receiving TB
treatment in private facilities unlinked to the NTP are not captured in this survey, and those
patients may have different socio-demographic characteristics and may face different costs. In
Lao PDR, however, there was only a limited number of private health facilities, and all the indi-
viduals with suspected TB who were identified in private facilities should be referred to public
health facilities and initiate TB treatment in public facilities. Fourth, the sampled facilities were
randomly selected based on the number of TB case notifications in 2017. This sampling
method tended to not select districts with a small number of TB case notifications where the
accessibility to healthcare services might be limited. The findings of this survey may underesti-
mate costs due to limited sampling of the population who have issues in accessing health care.
Fifth, this survey assessed costs incurred from the time of symptom onset to the end of TB
treatment. Therefore, costs after TB treatment has finished were not included.
Conclusions
The results of the survey showed that although TB diagnosis and treatment are provided free
of charge in Lao PDR, TB patients and their households incur substantial costs when they are
diagnosed with TB and they also lack financial protection. As non-medical and indirect costs
accounted for more than 80% of the total costs, providing free TB services is not enough, and
expansion of existing social protection mechanisms and/or implementation of new interven-
tions for TB patients are necessary to mitigate this financial burden and reduce the proportion
of households who experience catastrophic costs associated with TB.
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